Younger Patients With HER2+ Breast Cancer May Benefit from Surgery First
Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma
TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.
Finding Ways to Break the Mold in GU Oncology
Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.
Survival Outcomes Improve With TIL Presence in TNBC
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.
Increased Thyroid Cancer Risk Not Observed After Use of GLP1 Receptor Agonist
Patients who are predisposed to medullary thyroid cancer should be advised against the use of GLP1 agents.